Therachon
Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holdin Webb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit …
Therachon
Did you know?
WebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and … Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development …
Webb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and … WebbTherachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead …
Webb17 aug. 2024 · Therachon, a Swiss biotech company, has closed a $60 million round to fund its new developments in rare genetic disease treatments. Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024
WebbTherachon AG operates as a biotechnology company. The Company offers novel therapeutics for rare conditions with unmet medical need. Therachon serves customers …
Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon … billy molloy georgetown prephttp://theracion.com/ cynk in englishWebbFresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare disease company. cynko bor intermagWebb13 mars 2024 · Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2024 for $810 million. … billy molls alaska hunting adventuresWebb29 aug. 2024 · About Therachon. Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. cynk optimaWebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … billy mollsWebb5 sep. 2024 · Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome.These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer.The U.S. … billy molls gear list